Skip to main content
Category

Insights

Using Cutaneous Synuclein Biosignatures to Distinguish Parkinson’s Disease From Multiple System Atrophy

By Insights

A recent paper published in Neurology and co-authored by two of CND Life Sciences’ co-founders, Christopher Gibbons and Roy Freeman (and other academic colleagues), presented the first-ever data suggesting the possibility that measurable pathological markers in the skin can reveal distinct biological characteristics to help separate one type of synucleinopathy from another.

Read More

A Lab Like No Other

By Insights

The mission of the clinical laboratory at CND Life Sciences—to provide timely and accurate test results that aid in the diagnosis and treatment of patients—may not seem different from that of other
labs, but behind this mission you’ll find a unique working environment where the quality of personal interactions and the culture are as important as the quality of the test results.

Read More

Visit CND Life Sciences at AANEM in Nashville

By Insights

Be sure to stop by CND Life Sciences’ booth at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, September 21-24 in Nashville, TN. Learn about the complexities of diagnosing autonomic disorders and small fiber neuropathies and how CND’s Syn-One Test® and Small-Fiber Dx™ can help.

Read More